UNSPSC 51281610: Dibekacin

This classification denotes an aminoglycoside antibiotic with the molecular formula C18H37N5O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45ZFO9E525, chemically known as 3,4-dideoxykanamycin b but generally known as dibekacin, which bears US NIH Compound Identifier 3021. European Medicines Agency schedules Dibekacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07072MIG.

UNSPSC 51281610 Dibekacin is a Commodity code for a specific aminoglycoside antibiotic, but the recent state and local opportunities tagged under it do not reflect dibekacin procurement. Instead, the code shows activity for broader pharmaceutical supply through cooperative purchasing vehicles and emergency-response medical products. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride antibiotics totaling $2,999,999.11 over three years, and Seminole County, Florida issued an Invitation for Bid in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for community health initiatives. The issuing bodies are state health departments and county public health authorities using cooperative purchasing consortia and competitive bidding to source pharmaceuticals and emergency medical supplies. No set-aside or preference programs were identified in the recent awards.

Geographic activity includes Illinois and Florida, with both procurements tied to public health and emergency response missions. The Illinois award to Chartwell Rx LLC through MMCAP Infuse represents a state-level piggyback contract with an initial 12-month term and two renewal options, while Seminole County's bid for naloxone and deactivation systems carries a two-year initial term plus one-year renewal option and includes FEMA compliance requirements. The code shows limited recent activity and a mismatch between its nominal scope (dibekacin, a specific antibiotic) and the actual work being bought (broad pharmaceutical warehouse supply and emergency medical products). Firms pursuing activity here should focus on cooperative purchasing frameworks and county-level emergency health procurement rather than dibekacin-specific supply.